Cargando…

Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency

During the last 2 decades, the continued development and the large-scale production of polyclonal immune serum globulin (ISG) preparations with improved safety and tolerability profiles have allowed treatment to focus on quality of life and long-term freedom from the complications of primary immune...

Descripción completa

Detalles Bibliográficos
Autor principal:	Berger, Melvin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2008
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127239/ https://www.ncbi.nlm.nih.gov/pubmed/18424340 http://dx.doi.org/10.1016/j.iac.2008.01.008

Ejemplares similares

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
por: Skoda-Smith, Suzanne, et al.
Publicado: (2010)

Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients
por: Schroeder, H. W., et al.
Publicado: (2012)

Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies
por: Shabaninejad, Hosein, et al.
Publicado: (2017)

Trough Concentrations of Specific Antibodies in Primary Immunodeficiency Patients Receiving Intravenous Immunoglobulin Replacement Therapy
por: Hassin, Ori, et al.
Publicado: (2021)

What Is the Burden of Immunoglobulin Replacement Therapy in Adult Patients With Primary Immunodeficiencies? A Systematic Review
por: Jones, Georgina L., et al.
Publicado: (2018)

Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy
por: Gernez, Yael, et al.
Publicado: (2018)

Practise of Immunoglobulin Replacement Therapy in Primary and Secondary Immunodeficiencies: A Single Centre Experience from Malaysia
por: Zahari, Nurul Hidayah, et al.
Publicado: (2023)

Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy
por: Koterba, Alan P, et al.
Publicado: (2014)

Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study
por: Vultaggio, Alessandra, et al.
Publicado: (2015)

Cytokine dysregulation despite immunoglobulin replacement therapy in common variable immunodeficiency (CVID)
por: Poto, Remo, et al.
Publicado: (2023)

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
por: Mallick, Rajiv, et al.
Publicado: (2018)

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes
por: Mallick, Rajiv, et al.
Publicado: (2022)

A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases
por: Epland, Kristin, et al.
Publicado: (2022)

British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy
por: Grigoriadou, S, et al.
Publicado: (2022)

Increased Access to Immunoglobulin Replacement Therapy for Patients with Primary Immunodeficiency in Poland Based on Clinical Usage Data of Immunoglobulin G over a 5-Year Period
por: Więsik-Szewczyk, Ewa, et al.
Publicado: (2023)

Subcutaneous Immunoglobulin-G Replacement Therapy with Preparations Currently Available in the United States for Intravenous or Intramuscular Use: Reasons and Regimens
por: Chouksey, Akhilesh, et al.
Publicado: (2005)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children
por: Kriván, Gergely, et al.
Publicado: (2022)

Proteomic Analysis of Sera from Common Variable Immunodeficiency Patients Undergoing Replacement Intravenous Immunoglobulin Therapy
por: Spadaro, Giuseppe, et al.
Publicado: (2011)

Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies
por: Wiesik-Szewczyk, Ewa, et al.
Publicado: (2020)

Primary Immune Deficiency: Patients’ Preferences for Replacement Immunoglobulin Therapy
por: Gonzalez, Juan Marcos, et al.
Publicado: (2022)

Advances of gene therapy for primary immunodeficiencies
por: Candotti, Fabio
Publicado: (2016)

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
por: Kobrynski, Lisa
Publicado: (2012)

Subcutaneous immunoglobulin therapy for adult patients with primary immunodeficiency disease: Qatar experience
por: Thalappil, Sherin, et al.
Publicado: (2023)

Human normal immunoglobulin in the treatment of primary immunodeficiency diseases
por: Wood, Philip
Publicado: (2012)

Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment
por: Espanol, Teresa, et al.
Publicado: (2014)

Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia
por: Compagno, Nicolò, et al.
Publicado: (2014)

Differential immunomodulation of T-cells by immunoglobulin replacement therapy in primary and secondary antibody deficiency
por: Dinh, Tri, et al.
Publicado: (2019)

II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies
por: Goudouris, Ekaterini Simões, et al.
Publicado: (2017)

Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
por: Gerth, William C, et al.
Publicado: (2014)

Immunoglobulin Replacement Therapy Versus Antibiotic Prophylaxis as Treatment for Incomplete Primary Antibody Deficiency
por: Smits, Bas M., et al.
Publicado: (2020)

Neonatal sepsis and transient immunodeficiency: Potential for novel immunoglobulin therapies?
por: Beudeker, Coco R., et al.
Publicado: (2022)

Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
por: Gill, Parwinder K., et al.
Publicado: (2018)

Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
por: Alsina, Laia, et al.
Publicado: (2021)

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy
por: Orange, J S, et al.
Publicado: (2012)

Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
por: Keith, Paul K., et al.
Publicado: (2022)

Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency
por: Ducruet, Thierry, et al.
Publicado: (2011)

Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
por: Gerth, William C, et al.
Publicado: (2014)

Does Intravenous Immunoglobulin Therapy Prolong Immunodeficiency in Transient Hypogammaglobulinemia of Infancy?
por: Memmedova, Lale, et al.
Publicado: (2013)

Individualized immunoglobulin therapy in chronic immune‐mediated peripheral neuropathies*
por: Allen, Jeffrey A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cct90nbarihp1l9hgvbudfvmgm